These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 32017766)
1. Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans. Malafa S; Medits I; Aberle JH; Aberle SW; Haslwanter D; Tsouchnikas G; Wölfel S; Huber KL; Percivalle E; Cherpillod P; Thaler M; Roßbacher L; Kundi M; Heinz FX; Stiasny K PLoS Negl Trop Dis; 2020 Feb; 14(2):e0008034. PubMed ID: 32017766 [TBL] [Abstract][Full Text] [Related]
2. Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick-borne encephalitis and dengue virus infections. Roßbacher L; Malafa S; Huber K; Thaler M; Aberle SW; Aberle JH; Heinz FX; Stiasny K J Med Virol; 2023 Nov; 95(11):e29245. PubMed ID: 38009693 [TBL] [Abstract][Full Text] [Related]
3. Incorporation of IgG Depletion in a Neutralization Assay Facilitates Differential Diagnosis of Zika and Dengue in Secondary Flavivirus Infection Cases. Calvert AE; Boroughs KL; Laven J; Stovall JL; Luy BE; Kosoy OI; Huang CY J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618505 [TBL] [Abstract][Full Text] [Related]
4. Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection. Santos-Peral A; Luppa F; Goresch S; Nikolova E; Zaucha M; Lehmann L; Dahlstroem F; Karimzadeh H; Thorn-Seshold J; Winheim E; Schuster EM; Dobler G; Hoelscher M; Kümmerer BM; Endres S; Schober K; Krug AB; Pritsch M; Barba-Spaeth G; Rothenfusser S Nat Commun; 2024 Feb; 15(1):1696. PubMed ID: 38402207 [TBL] [Abstract][Full Text] [Related]
5. Different Cross-Reactivities of IgM Responses in Dengue, Zika and Tick-Borne Encephalitis Virus Infections. Stiasny K; Malafa S; Aberle SW; Medits I; Tsouchnikas G; Aberle JH; Holzmann H; Heinz FX Viruses; 2021 Mar; 13(4):. PubMed ID: 33807442 [TBL] [Abstract][Full Text] [Related]
6. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880 [TBL] [Abstract][Full Text] [Related]
7. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206 [TBL] [Abstract][Full Text] [Related]
8. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development. Elong Ngono A; Shresta S Front Immunol; 2019; 10():1316. PubMed ID: 31244855 [TBL] [Abstract][Full Text] [Related]
9. Use of the immunoglobulin G avidity assay to differentiate between recent Zika and past dengue virus infections. Furuya AKM; Hunt D; George KS; Dupuis AP; Kramer LD; Shi PY; Wong S Clin Sci (Lond); 2019 Apr; 133(7):859-867. PubMed ID: 30902827 [TBL] [Abstract][Full Text] [Related]
10. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS mBio; 2016 Jul; 7(4):. PubMed ID: 27435464 [TBL] [Abstract][Full Text] [Related]
11. Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus. Bailey MJ; Broecker F; Duehr J; Arumemi F; Krammer F; Palese P; Tan GS mBio; 2019 Apr; 10(2):. PubMed ID: 30940710 [TBL] [Abstract][Full Text] [Related]
12. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization. Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259 [TBL] [Abstract][Full Text] [Related]
15. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine. Li Y; Merbah M; Wollen-Roberts S; Beckman B; Mdluli T; Curtis DJ; Currier JR; Mendez-Rivera L; Dussupt V; Krebs SJ; De La Barrera R; Michael NL; Paquin-Proulx D; Eller MA; Koren MA; Modjarrad K; Rolland M EBioMedicine; 2023 Nov; 97():104815. PubMed ID: 37793212 [TBL] [Abstract][Full Text] [Related]
16. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge. De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091 [TBL] [Abstract][Full Text] [Related]
19. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies. Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Simmons M; Porter KR; Escamilla J; Graham R; Watts DM; Eckels KH; Hayes CG Am J Trop Med Hyg; 1998 Feb; 58(2):144-51. PubMed ID: 9502595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]